Fingolimod (sphingosine 1-phosphate receptor agonist) reduced frequencies of cTfh17, cTfh17.1, and CXCR5+CD25hi cTfr cells, but increased cTfh1 cells in MS patients (145). This evidence concerns the gene CXCR5 and myeloid sarcoma.